Aspects of the present invention relate inter alia to compositions which may have utility as anti-microbials. Such antimicrobial compositions may be for use in promoting wound healing and/or the treatment of microbial infections. In certain embodiments, the invention relates to an antimicrobial composition and/or combinations comprising copper gluconate and zinc gluconate which may be for use in treating and/or preventing infections and/or promoting wound healing. Certain aspects of the present invention further elate to an antimicrobial composition and/or device comprising copper gluconate, zinc gluconate and Lactobacillus plantarum for use in treating infections and/or promoting wound healing. Also encompassed by the present invention are methods of treating microbial and/or fungal infections in a subject, for example infections of the genital tract. Aspects of the present invention include a composition comprising a zinc salt and a copper salt, wherein the zinc salt is zinc gluconate and the copper salt is copper gluconate.

The present invention relates to methods for producing a mix of natural high polymeric and double stranded RNA from yeast (like Saccharomyces Cerevisiae), which can be used as dietary supplement, veterinary drug and medicine. The claimed invention relates to biotechnology and immunology, and to the production of the novel drug with a wide spectrum of antiviral activity on the basis RNA from yeast (like Saccharomyces Cerevisiae) for the treatment and prevention of diseases of viral etiology. Also, as a concomitant medication for the inflammatory diseases associated with bacterial infections. Our RNA works inside its own cell and activates a whole cascade of cellular and humoral immunity and therefore can be used as a polyvalent viral vaccine. By-products are high-purity proteins, low polymer RNA, microRNAs and oligonucleotides.

The present invention relates to methods for producing a mix of natural high polymeric and double stranded RNA from yeast (like Saccharomyces Cerevisiae), which can be used as dietary supplement, veterinary drug and medicine. The claimed invention relates to biotechnology and immunology, and to the production of the novel drug with a wide spectrum of antiviral activity on the basis RNA from yeast (like Saccharomyces Cerevisiae) for the treatment and prevention of diseases of viral etiology. Also, as a concomitant medication for the inflammatory diseases associated with bacterial infections. Our RNA works inside its own cell and activates a whole cascade of cellular and humoral immunity and therefore can be used as a polyvalent viral vaccine. By-products are high-purity proteins, low polymer RNA, microRNAs and oligonucleotides.

A health food for promotion of quality of sleepy and metabolism, comprises the following components with a weight ratio of: 44.93 Milligrams ±25% of Magnesium (Mg), 3.8 Milligrams (±25%) of Zinc (Zn), 40 Micrograms (±25%) of Selenium (Se) and 40 Micrograms (±25%) of Chromium (Cr). Magnesium has the effect to promote ability of cardiovascular disease prevention; zinc can increase the power of mitochondria and enhance the power of metabolism, selenium serves to reduce risks of suffering from cancers and suppress the probability of infection of RNA virus, and Chromium has the effect of reduction of type 2 diabetes. A combination of above mentioned components has the overall effect of promotion of sleep quality, reduction of demand of sleep and increase abilities of diseases preventions.

A health food for promotion of quality of sleepy and metabolism, comprises the following components with a weight ratio of: 44.93 Milligrams ±25% of Magnesium (Mg), 3.8 Milligrams (±25%) of Zinc (Zn), 40 Micrograms (±25%) of Selenium (Se) and 40 Micrograms (±25%) of Chromium (Cr). Magnesium has the effect to promote ability of cardiovascular disease prevention; zinc can increase the power of mitochondria and enhance the power of metabolism, selenium serves to reduce risks of suffering from cancers and suppress the probability of infection of RNA virus, and Chromium has the effect of reduction of type 2 diabetes. A combination of above mentioned components has the overall effect of promotion of sleep quality, reduction of demand of sleep and increase abilities of diseases preventions.

An oral pharmabiotic system is disclosed for improving oral, dental, and systemic health by repopulating and reshaping the flora within a patient's oral environment in a manner that overcomes the deficiencies of prior oral probiotic products. By formulating the pharmabiotic system as a strip for adhesive placement within a patients' oral cavity, preferably against the buccal mucosa, alveolar mucosa, oral labial mucosa, or a dental appliance, and configuring the parameters of the strip such that neither disadhesion nor complete dissolution occurs for at least a period of at least three hours during daytime use and at least six hours during nighttime use, the probiotic payload contained within may remain in the oral cavity for a sufficient length of time required for the probiotics to activate, replicate, and displace existing harmful oral pathobiotics.

An oral pharmabiotic system is disclosed for improving oral, dental, and systemic health by repopulating and reshaping the flora within a patient's oral environment in a manner that overcomes the deficiencies of prior oral probiotic products. By formulating the pharmabiotic system as a strip for adhesive placement within a patients' oral cavity, preferably against the buccal mucosa, alveolar mucosa, oral labial mucosa, or a dental appliance, and configuring the parameters of the strip such that neither disadhesion nor complete dissolution occurs for at least a period of at least three hours during daytime use and at least six hours during nighttime use, the probiotic payload contained within may remain in the oral cavity for a sufficient length of time required for the probiotics to activate, replicate, and displace existing harmful oral pathobiotics.

The invention relates to a pharmaceutical composition comprising (i) a live strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp, (ii) an attenuated strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp or, (iii) a medically active substance isolated from a strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp.

The invention relates to a pharmaceutical composition comprising (i) a live strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp, (ii) an attenuated strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp or, (iii) a medically active substance isolated from a strain from the genus of Kazachstania spp, Acetobacter spp. and/or Stenotrophomonas spp.

The present invention discloses a genetically engineered Kluyveromyces sp. yeast cell comprising at least a genetic modification that inactivates or deletes a nucleic acid sequence encoding for transcription factor SEQ ID No. 2, particularly Haal. The genetically engineered yeast cell according to this invention has an improvement of lactic acid tolerance, lactic acid production or a combination thereof as compared to the parental.